Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Maolactin on GI Health
NCT06104917Phase 3Completed
- Sponsor
- RDC Clinical
- Start
- Feb 2024
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial (3 arms), sponsored by RDC Clinical. Primary endpoint: Change in upper gastrointestinal symptoms at Day 56. Started Feb 2024; status: completed.
Beyond the preview
Go deeper on NCT06104917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06104917.